Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region

被引:72
作者
Agrawal, Mukta [1 ]
Saraf, Swarnlata [2 ]
Saraf, Shailendra [2 ,3 ]
Antimisiaris, Sophia G. [4 ,5 ]
Hamano, Nobuhito [6 ]
Li, Shyh-Dar [6 ]
Chougule, Mahavir [7 ,8 ]
Shoyele, Sunday A. [9 ]
Gupta, Umesh [10 ]
Ajazuddin [1 ]
Alexander, Amit [1 ]
机构
[1] Rungta Coll Pharmaceut Sci & Res, Dept Pharmaceut, Bhilai, Chhattisgarh, India
[2] Pt Ravishankar Shukla Univ, Univ Inst Pharm, Dept Pharmaceut, Raipur, Chhattisgarh, India
[3] Durg Univ, Govt Vasudev Vaman Patankar Girls PG Coll Campus, Durg, Chhattisgarh, India
[4] Univ Patras, Dept Pharm, Lab Pharmaceut Technol, Rion 26510, Greece
[5] FORTH ICE HT, Inst Chem Engn, Dept Pharm, Patras 25104, Greece
[6] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T IZ3, Canada
[7] Univ Mississippi, Sch Pharm, Dept Pharmaceut & Drug Delivery, Oxford, MS 38677 USA
[8] Univ Mississippi, Res Inst Pharmaceut Sci, University, MS 38677 USA
[9] Thomas Jefferson Univ, Coll Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19107 USA
[10] Cent Univ Rajasthan, Sch Chem Sci & Pharm, Dept Pharm, Kishangarh 305817, Ajmer, India
关键词
Alzheimer; nanotechnology; BBB; lactoferrin; SLN; NLC; SOLID-LIPID NANOPARTICLES; GLUTATHIONE PEGYLATED LIPOSOMES; DUAL-FUNCTIONAL NANOPARTICLES; POMEGRANATE SEED OIL; A-BETA AGGREGATION; N-MC CELLS; IN-VITRO; AMYLOID-BETA; NEURODEGENERATIVE DISEASES; MEDIATED TRANSPORT;
D O I
10.1080/17425247.2018.1471058
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Brain is supposed to be the most complicated part of the body which is very far from the reach of drug moieties. The drug entry in to the brain region depends upon various factors, and among those, the blood-brain-barrier remains the most prominent one. This barrier restricts the entry of almost all the drug and most of the essential biological components like proteins, peptides, etc. and hinders treatment of the CNS disorders. Alzheimer Disease (AD) is one such brain disorder, more specifically a neurodegenerative disorder which primarily affects the older adults. Areas covered: From solubility enhancement to targeted delivery, the nanoparticulate system became the answer for almost all the criticality related to drug delivery. Hence, nanoparticulate drug carrier system has been widely utilizing to remove the hurdles of brain drug delivery. Keeping this in mind, we have underlined the proficiencies of the nanocarrier systems which claim to improve the drug efficacy for the treatment of the AD. Expert opinion: The nanotechnological approaches are highly exploited by the researchers to enhance the drug permeation across the BBB to improve its bioavailability and efficacy by protecting the drug from peripheral degradation. However, still in this area of drug targeting provides vast scope for discoveries towards the enhancement of drug efficacy through surface modifications, site specification, reduced toxicity of the nanocarrier system and so on.
引用
收藏
页码:589 / 617
页数:29
相关论文
共 236 条
[1]  
ADEM A, 1990, PARKINSONS DIS, V2, P113
[2]   Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].
Agnihotri, SA ;
Mallikarjuna, NN ;
Aminabhavi, TM .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28
[3]   Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease [J].
Agrawal, Mukta ;
Ajazuddin ;
Tripathi, Dulal K. ;
Saraf, Swarnlata ;
Saraf, Shailendra ;
Antimisiaris, Sophia G. ;
Mourtas, Spyridon ;
Hammarlund-Udenaes, Margareta ;
Alexander, Amit .
JOURNAL OF CONTROLLED RELEASE, 2017, 260 :61-77
[4]   Protein aggregation diseases: pathogenicity and therapeutic perspectives [J].
Aguzzi, Adriano ;
O'Connor, Tracy .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :237-248
[5]   Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy [J].
Agyare, Edward K. ;
Curran, Geoffry L. ;
Ramakrishnan, Muthu ;
Yu, Caroline C. ;
Poduslo, Joseph F. ;
Kandimalla, Karunya K. .
PHARMACEUTICAL RESEARCH, 2008, 25 (11) :2674-2684
[6]   Advancement in stimuli triggered in situ gelling delivery for local and systemic route [J].
Ajazuddin ;
Alexander, Amit ;
Khan, Junaid ;
Giri, Tapan Kumar ;
Tripathi, Dulal Krishna ;
Saraf, Swarnlata ;
Saraf, Shailendra .
EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (12) :1573-1592
[7]   Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor [J].
Aktas, Y ;
Andrieux, K ;
Alonso, MJ ;
Calvo, P ;
Gürsoy, RN ;
Couvreur, P ;
Çapan, Y .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 298 (02) :378-383
[8]   Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives [J].
Alexander, Amit ;
Ajazuddin ;
Patel, Ravish J. ;
Saraf, Swarnlata ;
Saraf, Shailendra .
JOURNAL OF CONTROLLED RELEASE, 2016, 241 :110-124
[9]   Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate [J].
Alexander, Amit ;
Saraf, Swarnlata ;
Saraf, Shailendra .
CURRENT DRUG DELIVERY, 2016, 13 (04) :621-630
[10]   A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates [J].
Alexander, Amit ;
Saraf, Swarnlata ;
Saraf, Shailendra .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (12) :1954-1961